Telehealth firm Ro has paused promoting of the weight problems drug Wegovy because the drug suffers shortages, a reversal in aggressive promotional efforts by the supplier that concerned splashy adverts in subway stations.
Novo Nordisk, the maker of Wegovy, mentioned final month it might restrict its beginning doses for brand spanking new sufferers and pause promoting of the drug to keep away from stimulating additional demand. “Following Novo’s lead, we’ve paused key promotional efforts (together with all TV),” Zachariah Reitano, chief govt of Ro, wrote Monday in a put up on its web site. “We’re reassessing different promotional plans as nicely.”
Ro mentioned in an electronic mail that it wasn’t requested by Novo to pause promoting, however somewhat it selected to do that independently.
Wegovy has exploded in reputation for its effectiveness in serving to individuals shed weight, main telehealth firms to supply the drug in addition to related medicines like Ozempic and Mounjaro. WW Worldwide, referred to as WeightWatchers, this yr purchased telehealth firm Sequence, which prescribes these medicine. And Noom, which has lengthy endorsed a psychological method to weight reduction, additionally began providing Wegovy.
Ro was particularly aggressive in advertising its weight problems program, plastering adverts exhibiting individuals injecting medicines into their abdomens on New York Metropolis subway partitions and turnstiles. Ro even named Wegovy by identify in these adverts, wading right into a regulatory grey space of direct-to-consumer drug promoting.
The strikes Ro is now taking present the ripple results Wegovy’s shortages are having on telehealth firms which have raced into the area. Reitano mentioned in his put up that Ro can also be issuing credit to customers if they will’t choose up Wegovy, and the corporate is making an attempt so as to add extra remedy choices.
Competitors to supply weight reduction medicine on to customers has been heated. As extra telehealth suppliers have jumped onto the development, Calibrate, which began prescribing weight problems medicines even earlier than Wegovy was accredited, just lately mentioned it would begin to focus extra on partnering with employers.
Novo expects individuals to have issue filling decrease doses of Wegovy via September, however there could possibly be one other weight problems drug available on the market quickly. Eli Lilly’s Mounjaro is presently accredited for diabetes however has been used off-label for weight reduction. It’s proven potential for even better weight reduction than Wegovy, and analysts count on it could possibly be accredited as an weight problems remedy later this yr.
STAT’s protection of power well being points is supported by a grant from Bloomberg Philanthropies. Our monetary supporters should not concerned in any choices about our journalism.